[
  {
    "ts": null,
    "headline": "How To Retire In 2025 On Dividends",
    "summary": "Ready to retire? Read more on how those preparing for retirement can develop a portfolio of dividend stocks.",
    "url": "https://finnhub.io/api/news?id=675fb94138efd8a127b6bb3c96d67b8d348920408a8ae12b348fea541e1ced30",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753904633,
      "headline": "How To Retire In 2025 On Dividends",
      "id": 136146668,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187824383/image_2187824383.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Ready to retire? Read more on how those preparing for retirement can develop a portfolio of dividend stocks.",
      "url": "https://finnhub.io/api/news?id=675fb94138efd8a127b6bb3c96d67b8d348920408a8ae12b348fea541e1ced30"
    }
  },
  {
    "ts": null,
    "headline": "GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise",
    "summary": "GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.",
    "url": "https://finnhub.io/api/news?id=00f752e8dd377f30ded6da2dc10dee00ca2174055de3b0c4721bf065bcbd8530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753890120,
      "headline": "GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise",
      "id": 136148857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.",
      "url": "https://finnhub.io/api/news?id=00f752e8dd377f30ded6da2dc10dee00ca2174055de3b0c4721bf065bcbd8530"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect",
    "summary": "ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.",
    "url": "https://finnhub.io/api/news?id=388471b9fc1b335b8964c97c96478f44f8ed157ddef7f09bf4ddeed96e977b37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753884660,
      "headline": "Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect",
      "id": 136148858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.",
      "url": "https://finnhub.io/api/news?id=388471b9fc1b335b8964c97c96478f44f8ed157ddef7f09bf4ddeed96e977b37"
    }
  },
  {
    "ts": null,
    "headline": "Merz Aesthetics Strengthens U.S. Commercial Leadership With Key Executive Hires",
    "summary": "RALEIGH, N.C., July 30, 2025--Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced two additions to its North America regional executive team: Chris Van Dyk, Vice President of U.S. Sales, and DJ Sethares, Vice President of U.S. Marketing. In their new roles, Van Dyk and Sethares will oversee all sales and marketing efforts, respectively, to drive growth across the Merz Aesthetics portfolio of brands in the United States.",
    "url": "https://finnhub.io/api/news?id=4d8bc5d40761edb43ec1d4adc3e56e6c70cac3b3d8d51df9789747cd68512306",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753877100,
      "headline": "Merz Aesthetics Strengthens U.S. Commercial Leadership With Key Executive Hires",
      "id": 136129711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "RALEIGH, N.C., July 30, 2025--Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced two additions to its North America regional executive team: Chris Van Dyk, Vice President of U.S. Sales, and DJ Sethares, Vice President of U.S. Marketing. In their new roles, Van Dyk and Sethares will oversee all sales and marketing efforts, respectively, to drive growth across the Merz Aesthetics portfolio of brands in the United States.",
      "url": "https://finnhub.io/api/news?id=4d8bc5d40761edb43ec1d4adc3e56e6c70cac3b3d8d51df9789747cd68512306"
    }
  },
  {
    "ts": null,
    "headline": "J&J tests direct CAR-T marketing with first Carvykti ad",
    "summary": "The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier manufacturing struggles.",
    "url": "https://finnhub.io/api/news?id=64b97bd1f4a07ab775b692ada3bf147c65c156fa3bd34c50e31875fdfc124cbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753875414,
      "headline": "J&J tests direct CAR-T marketing with first Carvykti ad",
      "id": 136148859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier manufacturing struggles.",
      "url": "https://finnhub.io/api/news?id=64b97bd1f4a07ab775b692ada3bf147c65c156fa3bd34c50e31875fdfc124cbc"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare raises annual profit forecast on smaller tariff impact",
    "summary": "GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April.",
    "url": "https://finnhub.io/api/news?id=431170e5657657b5d4701165859a399a5d20348b6c767c9a049ad8c9454f9d2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753875150,
      "headline": "GE HealthCare raises annual profit forecast on smaller tariff impact",
      "id": 136129712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GE HealthCare Technologies raised annual profit forecast on Wednesday, as the medical device maker expects a smaller hit from tariffs. The company expects adjusted profit of $4.43 to $4.63 per share for 2025, compared with its previous range of $3.90 to $4.10 per share. The forecast includes a 45-cent-per-share impact from tariffs, which is lower than the 85 cents or $500 million hit it expected in April.",
      "url": "https://finnhub.io/api/news?id=431170e5657657b5d4701165859a399a5d20348b6c767c9a049ad8c9454f9d2e"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Fund Q2 2025  Commentary",
    "summary": "Franklin Templeton reviews Q2 for ClearBridge Value Fund, highlighting AI-driven power picks and inflation hedges. Explore where they see opportunity next.",
    "url": "https://finnhub.io/api/news?id=b460b6ffacf228e5e2c51999d77430162c4da7479cafbc71b076706696b35c67",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753872900,
      "headline": "ClearBridge Value Fund Q2 2025  Commentary",
      "id": 136131852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178163747/image_2178163747.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Franklin Templeton reviews Q2 for ClearBridge Value Fund, highlighting AI-driven power picks and inflation hedges. Explore where they see opportunity next.",
      "url": "https://finnhub.io/api/news?id=b460b6ffacf228e5e2c51999d77430162c4da7479cafbc71b076706696b35c67"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Broadcom, Berkshire Hathaway, Johnson & Johnson, Oil-Dri Corp. of America and Park Aerospace",
    "summary": "Broadcom, Berkshire Hathaway, and J&J headline a strong slate of stocks, with rising momentum in AI, insurance, and pharma growth drivers.",
    "url": "https://finnhub.io/api/news?id=2c4b2307b98c2090c23da446bb0d00ff4c351ac181f63a462b4648251ec811cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753870620,
      "headline": "The Zacks Analyst Blog Highlights Broadcom, Berkshire Hathaway, Johnson & Johnson, Oil-Dri Corp. of America and Park Aerospace",
      "id": 136129559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Broadcom, Berkshire Hathaway, and J&J headline a strong slate of stocks, with rising momentum in AI, insurance, and pharma growth drivers.",
      "url": "https://finnhub.io/api/news?id=2c4b2307b98c2090c23da446bb0d00ff4c351ac181f63a462b4648251ec811cb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
    "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
    "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868462,
      "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
      "id": 136129640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
      "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy’s",
    "url": "https://finnhub.io/api/news?id=f63c6944462f30737ec8b786376be44a7ada2fbca06ee2972a78d9db196ebed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753864200,
      "headline": "[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136129715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy’s",
      "url": "https://finnhub.io/api/news?id=f63c6944462f30737ec8b786376be44a7ada2fbca06ee2972a78d9db196ebed8"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: A Bet On Global Healthcare Recovery",
    "summary": "IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.",
    "url": "https://finnhub.io/api/news?id=efbb41a862d9a020aa33084c6f7cb09c8955e6659667bd377b0249cad00c608b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753839218,
      "headline": "IXJ: A Bet On Global Healthcare Recovery",
      "id": 136127584,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174965679/image_174965679.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.",
      "url": "https://finnhub.io/api/news?id=efbb41a862d9a020aa33084c6f7cb09c8955e6659667bd377b0249cad00c608b"
    }
  }
]